Dr. Anne Messer was one of two experts chosen to present a webinar for The Scientist (March 8, 2018.) Antibodies are the fastest growing class of synthetic therapeutics, and Dr. Messer’s presentation covered their development and use as therapeutics and markers for neurodegenerative diseases. She described cutting-edge design and optimization approaches, as well as offering insight on future directions in antibody engineering. Human stem cell lines and assays at NSCI allow screening and testing for which of these engineered antibodies and their variants should be carried forward as clinical drug candidates. The session had 581 registrants and 148 live viewers who also asked questions at the end of the presentations.